Artelo Biosciences Inc Cash Flow-to-Debt Ratio
Artelo Biosciences Inc cash flow-to-debt ratio. Artelo Biosciences Inc (ARTL) has a Cash Flow-to-Debt Ratio of -3.44x as of June 2026, meaning its operating cash flow of $-5.03 Million could theoretically repay -3% of its total liabilities ($1.46 Million) in one year. See ARTL financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Artelo Biosciences Inc (2015–2025)
Cash flow-to-debt ratio of Artelo Biosciences Inc from 2015 to 2025. Historical debt coverage capacity for Artelo Biosciences Inc across 11 annual periods. Also explore ARTL year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Artelo Biosciences Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Artelo Biosciences Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Artelo Biosciences Inc. For the full cash flow conversion analysis, see ARTL cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.09x | $-8.52 Million | $4.07 Million | ▲ +53.9% |
| 2024 | -4.54x | $-8.35 Million | $1.84 Million | ▲ +28.7% |
| 2023 | -6.36x | $-8.21 Million | $1.29 Million | ▲ +18.9% |
| 2022 | -7.84x | $-8.01 Million | $1.02 Million | ▲ +24.3% |
| 2021 | -10.36x | $-6.14 Million | $593.00K | ▼ -19.4% |
| 2020 | -8.68x | $-4.35 Million | $501.00K | ▼ -217.4% |
| 2019 | -2.73x | $-2.79 Million | $1.02 Million | ▲ +9.7% |
| 2018 | -3.03x | $-1.61 Million | $531.97K | ▲ +58.9% |
| 2017 | -7.37x | $-216.82K | $29.44K | ▼ -592.8% |
| 2016 | -1.06x | $-18.49K | $17.39K | ▲ +86.3% |
| 2015 | -7.76x | $-13.50K | $1.74K | — |